What type of study is this?

December 5, 2025Journal of Liver CancerOpen Access

Re-evaluating DAA therapy in active hepatocellular carcinoma: from controversy to clinical considerations

View Full Paper

Ask AI

Bookmark

Authors

Large-scale studies reveal DAA therapy may not harm oncologic outcomes in hepatocellular carcinoma, suggesting a need for tailored approaches.

DAA therapy shows a neutral effect on oncologic outcomes in hepatocellular carcinoma patients, with proper management.
Survival rates are better when DAA therapy is close to curative treatments in hepatocellular carcinoma cases.
Observational data from multiple studies indicate the lack of universal guidelines for hepatocellular carcinoma and DAA therapy combination.
Individualized treatment decisions are crucial, factoring in tumor biology and patient health status for hepatocellular carcinoma management.

Jeon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Large-scale studies reveal DAA therapy may not harm oncologic outcomes in hepatocellular carcinoma, suggesting a need for tailored approaches.